APO Research
Talk to an analyst

APO RESEARCH · REPORT

Somatostatin

Somatostatin is one kind of hormone. It is widely distributed throughout the body, especially in the hypothalamus and pancreas. It also acts as an important regulator of endocrine and nervous system function by inhibiting the secretion of several other hormones such as growth hormone, insulin, and gastrin.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Somatostatin is one kind of hormone. It is widely distributed throughout the body, especially in the hypothalamus and pancreas. It also acts as an important regulator of endocrine and nervous system function by inhibiting the secretion of several other hormones such as growth hormone, insulin, and gastrin.

Selected research

Market Outlook & Growth Opportunities

Global Somatostatin Market Outlook and Growth Opportunities 2026

22 December 2025201 pages

Choose your research edition.

Industry ResearchSomatostatin Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Somatostatin Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Somatostatin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Somatostatin Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Somatostatin Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

Somatostatin is one kind of hormone. It is widely distributed throughout the body, especially in the hypothalamus and pancreas. It also acts as an important regulator of endocrine and nervous system function by inhibiting the secretion of several other hormones such as growth hormone, insulin, and gastrin.

Global Somatostatin key players include Merck (Schweiz) AG, SANOFI-AVENTIS FRANCE, Lyomark Pharma GmbH, ALFA WASSERMANN S.p.A., HYBIO, etc. Global top five manufacturers hold a share over 65%.

China is the largest market, followed by Europe and India.

Read the full market overview

This report provides an overview of the global Somatostatin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Somatostatin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Somatostatin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Somatostatin market size, projected growth trends, production technologies, key applications, and end-use industries.

Somatostatin Segment by Company

Merck (Schweiz) AG

SANOFI-AVENTIS FRANCE

Lyomark Pharma GmbH

ALFA WASSERMANN S.p.A.

Polypeptide Laboratories, Inc

SAMARTH

UBPL

HYBIO

TianTaiShan

Yangtze River

Siyao

Shuangcheng

Hainan Zhonghe

SL PHARM

Wuhan Hualong

Qingdao Guoda

Chengdu Shengnuo

Longjin

Somatostatin Segment by Type

0.25mg/pcs

0.75mg/pcs

3mg/pcs

Somatostatin Segment by Application

Hormonal Disorder

Oncology

Metabolic Disorder

Others

Somatostatin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Somatostatin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Somatostatin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Somatostatin significant trends, drivers, influence factors in global and regions.

6. To analyze Somatostatin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Somatostatin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Somatostatin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Somatostatin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Somatostatin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Somatostatin industry.

Chapter 3: Detailed analysis of Somatostatin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Somatostatin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Somatostatin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Somatostatin Industry Trends Table 2. Somatostatin Industry Drivers Table 3. Somatostatin Industry Opportunities and Challenges Table 4. Somatostatin Industry Restraints Table 5. Global Somatostatin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Somatostatin Revenue Share by Company (2021-2026) Table 7. Global Somatostatin Sales Volume by Company (K Pcs) & (2021-2026) Table 8. Global Somatostatin Sales Volume Share by Company (2021-2026) Table 9. Global Somatostatin Average Price (USD/Pcs) of Company (2021-2026) Table 10. Global Somatostatin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Somatostatin Key Company Manufacturing Base & Headquarters Table 12. Global Somatostatin Company, Product Type & Application Table 13. Global Somatostatin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Somatostatin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 0.25mg/pcs Table 18. Significant Companies of 0.75mg/pcs Table 19. Significant Companies of 3mg/pcs Table 20. Global Somatostatin Sales Volume by Type 2021 VS 2025 VS 2032 (K Pcs) Table 21. Global Somatostatin Sales Volume by Type (2021-2026) & (K Pcs) Table 22. Global Somatostatin Sales Volume by Type (2027-2032) & (K Pcs) Table 23. Global Somatostatin Sales Volume Share by Type (2021-2026) Table 24. Global Somatostatin Sales Volume Share by Type (2027-2032) Table 25. Global Somatostatin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Somatostatin Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Somatostatin Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Somatostatin Sales Value Share by Type (2021-2026) Table 29. Global Somatostatin Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hormonal Disorder Table 31. Significant Companies of Oncology Table 32. Significant Companies of Metabolic Disorder Table 33. Significant Companies of Others Table 34. Global Somatostatin Sales Volume by Application 2021 VS 2025 VS 2032 (K Pcs) Table 35. Global Somatostatin Sales Volume by Application (2021-2026) & (K Pcs) Table 36. Global Somatostatin Sales Volume by Application (2027-2032) & (K Pcs) Table 37. Global Somatostatin Sales Volume Share by Application (2021-2026) Table 38. Global Somatostatin Sales Volume Share by Application (2027-2032) Table 39. Global Somatostatin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Somatostatin Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Somatostatin Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Somatostatin Sales Value Share by Application (2021-2026) Table 43. Global Somatostatin Sales Value Share by Application (2027-2032) Table 44. Global Somatostatin Sales by Region: 2021 VS 2025 VS 2032 (K Pcs) Table 45. Global Somatostatin Sales by Region (2021-2026) & (K Pcs) Table 46. Global Somatostatin Sales Market Share by Region (2021-2026) Table 47. Global Somatostatin Sales by Region (2027-2032) & (K Pcs) Table 48. Global Somatostatin Sales Market Share by Region (2027-2032) Table 49. Global Somatostatin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Somatostatin Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Somatostatin Sales Value Share by Region (2021-2026) Table 52. Global Somatostatin Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Somatostatin Sales Value Share by Region (2027-2032) Table 54. Global Somatostatin Market Average Price (USD/Pcs) by Region (2021-2026) Table 55. Global Somatostatin Market Average Price (USD/Pcs) by Region (2027-2032) Table 56. Global Somatostatin Sales by Country: 2021 VS 2025 VS 2032 (K Pcs) Table 57. Global Somatostatin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Somatostatin Sales by Country (2021-2026) & (K Pcs) Table 59. Global Somatostatin Sales Market Share by Country (2021-2026) Table 60. Global Somatostatin Sales by Country (2027-2032) & (K Pcs) Table 61. Global Somatostatin Sales Market Share by Country (2027-2032) Table 62. Global Somatostatin Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Somatostatin Sales Value Market Share by Country (2021-2026) Table 64. Global Somatostatin Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Somatostatin Sales Value Market Share by Country (2027-2032) Table 66. Merck (Schweiz) AG Company Information Table 67. Merck (Schweiz) AG Business Overview Table 68. Merck (Schweiz) AG Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 69. Merck (Schweiz) AG Somatostatin Product Portfolio Table 70. Merck (Schweiz) AG Recent Development Table 71. SANOFI-AVENTIS FRANCE Company Information Table 72. SANOFI-AVENTIS FRANCE Business Overview Table 73. SANOFI-AVENTIS FRANCE Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 74. SANOFI-AVENTIS FRANCE Somatostatin Product Portfolio Table 75. SANOFI-AVENTIS FRANCE Recent Development Table 76. Lyomark Pharma GmbH Company Information Table 77. Lyomark Pharma GmbH Business Overview Table 78. Lyomark Pharma GmbH Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 79. Lyomark Pharma GmbH Somatostatin Product Portfolio Table 80. Lyomark Pharma GmbH Recent Development Table 81. ALFA WASSERMANN S.p.A. Company Information Table 82. ALFA WASSERMANN S.p.A. Business Overview Table 83. ALFA WASSERMANN S.p.A. Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 84. ALFA WASSERMANN S.p.A. Somatostatin Product Portfolio Table 85. ALFA WASSERMANN S.p.A. Recent Development Table 86. Polypeptide Laboratories, Inc Company Information Table 87. Polypeptide Laboratories, Inc Business Overview Table 88. Polypeptide Laboratories, Inc Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 89. Polypeptide Laboratories, Inc Somatostatin Product Portfolio Table 90. Polypeptide Laboratories, Inc Recent Development Table 91. SAMARTH Company Information Table 92. SAMARTH Business Overview Table 93. SAMARTH Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 94. SAMARTH Somatostatin Product Portfolio Table 95. SAMARTH Recent Development Table 96. UBPL Company Information Table 97. UBPL Business Overview Table 98. UBPL Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 99. UBPL Somatostatin Product Portfolio Table 100. UBPL Recent Development Table 101. HYBIO Company Information Table 102. HYBIO Business Overview Table 103. HYBIO Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 104. HYBIO Somatostatin Product Portfolio Table 105. HYBIO Recent Development Table 106. TianTaiShan Company Information Table 107. TianTaiShan Business Overview Table 108. TianTaiShan Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 109. TianTaiShan Somatostatin Product Portfolio Table 110. TianTaiShan Recent Development Table 111. Yangtze River Company Information Table 112. Yangtze River Business Overview Table 113. Yangtze River Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 114. Yangtze River Somatostatin Product Portfolio Table 115. Yangtze River Recent Development Table 116. Siyao Company Information Table 117. Siyao Business Overview Table 118. Siyao Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 119. Siyao Somatostatin Product Portfolio Table 120. Siyao Recent Development Table 121. Shuangcheng Company Information Table 122. Shuangcheng Business Overview Table 123. Shuangcheng Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 124. Shuangcheng Somatostatin Product Portfolio Table 125. Shuangcheng Recent Development Table 126. Hainan Zhonghe Company Information Table 127. Hainan Zhonghe Business Overview Table 128. Hainan Zhonghe Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 129. Hainan Zhonghe Somatostatin Product Portfolio Table 130. Hainan Zhonghe Recent Development Table 131. SL PHARM Company Information Table 132. SL PHARM Business Overview Table 133. SL PHARM Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 134. SL PHARM Somatostatin Product Portfolio Table 135. SL PHARM Recent Development Table 136. Wuhan Hualong Company Information Table 137. Wuhan Hualong Business Overview Table 138. Wuhan Hualong Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 139. Wuhan Hualong Somatostatin Product Portfolio Table 140. Wuhan Hualong Recent Development Table 141. Qingdao Guoda Company Information Table 142. Qingdao Guoda Business Overview Table 143. Qingdao Guoda Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 144. Qingdao Guoda Somatostatin Product Portfolio Table 145. Qingdao Guoda Recent Development Table 146. Chengdu Shengnuo Company Information Table 147. Chengdu Shengnuo Business Overview Table 148. Chengdu Shengnuo Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 149. Chengdu Shengnuo Somatostatin Product Portfolio Table 150. Chengdu Shengnuo Recent Development Table 151. Longjin Company Information Table 152. Longjin Business Overview Table 153. Longjin Somatostatin Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 154. Longjin Somatostatin Product Portfolio Table 155. Longjin Recent Development Table 156. Key Raw Materials Table 157. Raw Materials Key Suppliers Table 158. Somatostatin Distributors List Table 159. Somatostatin Customers List Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. Somatostatin Product Image Figure 2. Global Somatostatin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Somatostatin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Somatostatin Sales (2021-2032) & (K Pcs) Figure 5. Global Somatostatin Sales Average Price (USD/Pcs) & (2021-2032) Figure 6. Global Somatostatin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 0.25mg/pcs Image Figure 10. 0.75mg/pcs Image Figure 11. 3mg/pcs Image Figure 12. Global Somatostatin Sales Volume by Type (2021 VS 2025 VS 2032) & (K Pcs) Figure 13. Global Somatostatin Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Somatostatin Sales Volume Share by Type (2021-2032) Figure 15. Global Somatostatin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Somatostatin Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Somatostatin Sales Value Share by Type (2021-2032) Figure 18. Hormonal Disorder Image Figure 19. Oncology Image Figure 20. Metabolic Disorder Image Figure 21. Others Image Figure 22. Global Somatostatin Sales Volume by Application (2021 VS 2025 VS 2032) & (K Pcs) Figure 23. Global Somatostatin Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Somatostatin Sales Volume Share by Application (2021-2032) Figure 25. Global Somatostatin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Somatostatin Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Somatostatin Sales Value Share by Application (2021-2032) Figure 28. Global Somatostatin Sales by Region: 2021 VS 2025 VS 2032 (K Pcs) Figure 29. Global Somatostatin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Somatostatin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Somatostatin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Somatostatin Sales Value (2021-2032) & (US$ Million) Figure 33. North America Somatostatin Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Somatostatin Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Somatostatin Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Somatostatin Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Somatostatin Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Somatostatin Sales Value (2021-2032) & (US$ Million) Figure 39. South America Somatostatin Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Somatostatin Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Somatostatin Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Somatostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Somatostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Somatostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Somatostatin Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Somatostatin Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • 0.25mg/pcs
  • 0.75mg/pcs
  • 3mg/pcs
Applications
  • Hormonal Disorder
  • Oncology
  • Metabolic Disorder
  • Others
Companies covered
  • Merck (Schweiz) AG
  • SANOFI-AVENTIS FRANCE
  • Lyomark Pharma GmbH
  • ALFA WASSERMANN S.p.A.
  • Polypeptide Laboratories, Inc
  • SAMARTH
  • UBPL
  • HYBIO
  • TianTaiShan
  • Yangtze River
  • Siyao
  • Shuangcheng
  • Hainan Zhonghe
  • SL PHARM
  • Wuhan Hualong
  • Qingdao Guoda
  • Chengdu Shengnuo
  • Longjin

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Somatostatin Sales Value (2021-2032)
  4. 1.2.2 Global Somatostatin Sales Volume (2021-2032)
  5. 1.2.3 Global Somatostatin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Somatostatin Market Dynamics
  1. 2.1 Somatostatin Industry Trends
  2. 2.2 Somatostatin Industry Drivers
  3. 2.3 Somatostatin Industry Opportunities and Challenges
  4. 2.4 Somatostatin Industry Restraints
3 Somatostatin Market by Company
  1. 3.1 Global Somatostatin Company Revenue Ranking in 2025
  2. 3.2 Global Somatostatin Revenue by Company (2021-2026)
  3. 3.3 Global Somatostatin Sales Volume by Company (2021-2026)
  4. 3.4 Global Somatostatin Average Price by Company (2021-2026)
  5. 3.5 Global Somatostatin Company Ranking (2024-2026)
  6. 3.6 Global Somatostatin Company Manufacturing Base and Headquarters
  7. 3.7 Global Somatostatin Company Product Type and Application
  8. 3.8 Global Somatostatin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Somatostatin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Somatostatin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Somatostatin Market by Type
  1. 4.1 Somatostatin Type Introduction
  2. 4.1.1 0.25mg/pcs
  3. 4.1.2 0.75mg/pcs
  4. 4.1.3 3mg/pcs
  5. 4.2 Global Somatostatin Sales Volume by Type
  6. 4.2.1 Global Somatostatin Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Somatostatin Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Somatostatin Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Somatostatin Sales Value by Type
  10. 4.3.1 Global Somatostatin Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Somatostatin Sales Value by Type (2021-2032)
  12. 4.3.3 Global Somatostatin Sales Value Share by Type (2021-2032)
5 Somatostatin Market by Application
  1. 5.1 Somatostatin Application Introduction
  2. 5.1.1 Hormonal Disorder
  3. 5.1.2 Oncology
  4. 5.1.3 Metabolic Disorder
  5. 5.1.4 Others
  6. 5.2 Global Somatostatin Sales Volume by Application
  7. 5.2.1 Global Somatostatin Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Somatostatin Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Somatostatin Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Somatostatin Sales Value by Application
  11. 5.3.1 Global Somatostatin Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Somatostatin Sales Value by Application (2021-2032)
  13. 5.3.3 Global Somatostatin Sales Value Share by Application (2021-2032)
6 Somatostatin Regional Sales and Value Analysis
  1. 6.1 Global Somatostatin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Somatostatin Sales by Region (2021-2032)
  3. 6.2.1 Global Somatostatin Sales by Region: 2021-2026
  4. 6.2.2 Global Somatostatin Sales by Region (2027-2032)
  5. 6.3 Global Somatostatin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Somatostatin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Somatostatin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Somatostatin Sales Value by Region (2027-2032)
  9. 6.5 Global Somatostatin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Somatostatin Sales Value (2021-2032)
  12. 6.6.2 North America Somatostatin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Somatostatin Sales Value (2021-2032)
  15. 6.7.2 Europe Somatostatin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Somatostatin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Somatostatin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Somatostatin Sales Value (2021-2032)
  21. 6.9.2 South America Somatostatin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Somatostatin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Somatostatin Sales Value Share by Country, 2025 VS 2032
7 Somatostatin Country-level Sales and Value Analysis
  1. 7.1 Global Somatostatin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Somatostatin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Somatostatin Sales by Country (2021-2032)
  4. 7.3.1 Global Somatostatin Sales by Country (2021-2026)
  5. 7.3.2 Global Somatostatin Sales by Country (2027-2032)
  6. 7.4 Global Somatostatin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Somatostatin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Somatostatin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Somatostatin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Somatostatin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Somatostatin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Somatostatin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Somatostatin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Somatostatin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Somatostatin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Somatostatin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Somatostatin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Somatostatin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Somatostatin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Somatostatin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Somatostatin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Somatostatin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Somatostatin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Somatostatin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Somatostatin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Somatostatin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Somatostatin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Somatostatin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Somatostatin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Somatostatin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Somatostatin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Somatostatin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Somatostatin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Somatostatin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Somatostatin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Somatostatin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Somatostatin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Somatostatin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Somatostatin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Somatostatin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Somatostatin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Somatostatin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Somatostatin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Somatostatin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Somatostatin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Somatostatin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Somatostatin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Somatostatin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Somatostatin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Somatostatin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Somatostatin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Somatostatin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Somatostatin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Somatostatin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Somatostatin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Somatostatin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Somatostatin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Somatostatin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Somatostatin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Somatostatin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Somatostatin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Somatostatin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Somatostatin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Somatostatin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Somatostatin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Somatostatin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Somatostatin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Somatostatin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Somatostatin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Somatostatin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Somatostatin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Somatostatin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Somatostatin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Somatostatin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Somatostatin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Somatostatin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Somatostatin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Somatostatin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Somatostatin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Somatostatin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Somatostatin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Somatostatin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Somatostatin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Somatostatin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Somatostatin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Somatostatin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Somatostatin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Somatostatin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Somatostatin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Somatostatin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Somatostatin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Somatostatin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck (Schweiz) AG
  2. 8.1.1 Merck (Schweiz) AG Company Information
  3. 8.1.2 Merck (Schweiz) AG Business Overview
  4. 8.1.3 Merck (Schweiz) AG Somatostatin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck (Schweiz) AG Somatostatin Product Portfolio
  6. 8.1.5 Merck (Schweiz) AG Recent Developments
  7. 8.2 SANOFI-AVENTIS FRANCE
  8. 8.2.1 SANOFI-AVENTIS FRANCE Company Information
  9. 8.2.2 SANOFI-AVENTIS FRANCE Business Overview
  10. 8.2.3 SANOFI-AVENTIS FRANCE Somatostatin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 SANOFI-AVENTIS FRANCE Somatostatin Product Portfolio
  12. 8.2.5 SANOFI-AVENTIS FRANCE Recent Developments
  13. 8.3 Lyomark Pharma GmbH
  14. 8.3.1 Lyomark Pharma GmbH Company Information
  15. 8.3.2 Lyomark Pharma GmbH Business Overview
  16. 8.3.3 Lyomark Pharma GmbH Somatostatin Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Lyomark Pharma GmbH Somatostatin Product Portfolio
  18. 8.3.5 Lyomark Pharma GmbH Recent Developments
  19. 8.4 ALFA WASSERMANN S.p.A.
  20. 8.4.1 ALFA WASSERMANN S.p.A. Company Information
  21. 8.4.2 ALFA WASSERMANN S.p.A. Business Overview
  22. 8.4.3 ALFA WASSERMANN S.p.A. Somatostatin Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 ALFA WASSERMANN S.p.A. Somatostatin Product Portfolio
  24. 8.4.5 ALFA WASSERMANN S.p.A. Recent Developments
  25. 8.5 Polypeptide Laboratories, Inc
  26. 8.5.1 Polypeptide Laboratories, Inc Company Information
  27. 8.5.2 Polypeptide Laboratories, Inc Business Overview
  28. 8.5.3 Polypeptide Laboratories, Inc Somatostatin Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Polypeptide Laboratories, Inc Somatostatin Product Portfolio
  30. 8.5.5 Polypeptide Laboratories, Inc Recent Developments
  31. 8.6 SAMARTH
  32. 8.6.1 SAMARTH Company Information
  33. 8.6.2 SAMARTH Business Overview
  34. 8.6.3 SAMARTH Somatostatin Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 SAMARTH Somatostatin Product Portfolio
  36. 8.6.5 SAMARTH Recent Developments
  37. 8.7 UBPL
  38. 8.7.1 UBPL Company Information
  39. 8.7.2 UBPL Business Overview
  40. 8.7.3 UBPL Somatostatin Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 UBPL Somatostatin Product Portfolio
  42. 8.7.5 UBPL Recent Developments
  43. 8.8 HYBIO
  44. 8.8.1 HYBIO Company Information
  45. 8.8.2 HYBIO Business Overview
  46. 8.8.3 HYBIO Somatostatin Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 HYBIO Somatostatin Product Portfolio
  48. 8.8.5 HYBIO Recent Developments
  49. 8.9 TianTaiShan
  50. 8.9.1 TianTaiShan Company Information
  51. 8.9.2 TianTaiShan Business Overview
  52. 8.9.3 TianTaiShan Somatostatin Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 TianTaiShan Somatostatin Product Portfolio
  54. 8.9.5 TianTaiShan Recent Developments
  55. 8.10 Yangtze River
  56. 8.10.1 Yangtze River Company Information
  57. 8.10.2 Yangtze River Business Overview
  58. 8.10.3 Yangtze River Somatostatin Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Yangtze River Somatostatin Product Portfolio
  60. 8.10.5 Yangtze River Recent Developments
  61. 8.11 Siyao
  62. 8.11.1 Siyao Company Information
  63. 8.11.2 Siyao Business Overview
  64. 8.11.3 Siyao Somatostatin Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Siyao Somatostatin Product Portfolio
  66. 8.11.5 Siyao Recent Developments
  67. 8.12 Shuangcheng
  68. 8.12.1 Shuangcheng Company Information
  69. 8.12.2 Shuangcheng Business Overview
  70. 8.12.3 Shuangcheng Somatostatin Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Shuangcheng Somatostatin Product Portfolio
  72. 8.12.5 Shuangcheng Recent Developments
  73. 8.13 Hainan Zhonghe
  74. 8.13.1 Hainan Zhonghe Company Information
  75. 8.13.2 Hainan Zhonghe Business Overview
  76. 8.13.3 Hainan Zhonghe Somatostatin Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Hainan Zhonghe Somatostatin Product Portfolio
  78. 8.13.5 Hainan Zhonghe Recent Developments
  79. 8.14 SL PHARM
  80. 8.14.1 SL PHARM Company Information
  81. 8.14.2 SL PHARM Business Overview
  82. 8.14.3 SL PHARM Somatostatin Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 SL PHARM Somatostatin Product Portfolio
  84. 8.14.5 SL PHARM Recent Developments
  85. 8.15 Wuhan Hualong
  86. 8.15.1 Wuhan Hualong Company Information
  87. 8.15.2 Wuhan Hualong Business Overview
  88. 8.15.3 Wuhan Hualong Somatostatin Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Wuhan Hualong Somatostatin Product Portfolio
  90. 8.15.5 Wuhan Hualong Recent Developments
  91. 8.16 Qingdao Guoda
  92. 8.16.1 Qingdao Guoda Company Information
  93. 8.16.2 Qingdao Guoda Business Overview
  94. 8.16.3 Qingdao Guoda Somatostatin Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Qingdao Guoda Somatostatin Product Portfolio
  96. 8.16.5 Qingdao Guoda Recent Developments
  97. 8.17 Chengdu Shengnuo
  98. 8.17.1 Chengdu Shengnuo Company Information
  99. 8.17.2 Chengdu Shengnuo Business Overview
  100. 8.17.3 Chengdu Shengnuo Somatostatin Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Chengdu Shengnuo Somatostatin Product Portfolio
  102. 8.17.5 Chengdu Shengnuo Recent Developments
  103. 8.18 Longjin
  104. 8.18.1 Longjin Company Information
  105. 8.18.2 Longjin Business Overview
  106. 8.18.3 Longjin Somatostatin Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Longjin Somatostatin Product Portfolio
  108. 8.18.5 Longjin Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Somatostatin Value Chain Analysis
  2. 9.1.1 Somatostatin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Somatostatin Sales Mode & Process
  6. 9.2 Somatostatin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Somatostatin Distributors
  9. 9.2.3 Somatostatin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst